Anti-GD2 antibody shows promise in high-risk neuroblastoma patients

Описание к видео Anti-GD2 antibody shows promise in high-risk neuroblastoma patients

Ruth Ladenstein, MD, discusses toxicity and outcome of anti-GD2 antibody ch14.18/CHO in front-line, high-risk patients with neuroblastoma: Final results of the phase III immunotherapy randomisation (HR-NBL1/SIOPEN trial).

MDLinx Conference Coverage -American Society of Clinical Oncology 2016 Annual Meeting:
http://www.mdlinx.com/oncology/confer...

MDLinx: http://www.mdlinx.com/
Smartest Doc & Board Exam Prep: http://www.thesmartestdoc.com/
M3 USA: http://usa.m3.com/

Follow MDLinx:
Facebook -   / mdlinx  
Twitter -   / mdlinx  
Google+ - https://plus.google.com/+Mdlinx/

Комментарии

Информация по комментариям в разработке

Похожие видео